{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/leg-ulcer-venous/prescribing-information/pentoxifylline/","result":{"pageContext":{"chapter":{"id":"43ed3b03-6322-5690-8f85-b6e10a0b3d3e","slug":"pentoxifylline","fullItemName":"Pentoxifylline","depth":2,"htmlHeader":"<!-- begin field c37b65ec-0287-4df0-a67b-e74127bcac50 --><h2>Pentoxifylline</h2><!-- end field c37b65ec-0287-4df0-a67b-e74127bcac50 -->","summary":"","htmlStringContent":"<!-- begin item a6145385-4d0d-4915-8d6b-5d7bc0f5e35b --><!-- end item a6145385-4d0d-4915-8d6b-5d7bc0f5e35b -->","topic":{"id":"627b2b3c-014b-5543-8f89-0f3ffa6344ad","topicId":"4c5db985-9544-48b2-8c54-8915ec210739","topicName":"Leg ulcer - venous","slug":"leg-ulcer-venous","lastRevised":"Last revised in January 2021","chapters":[{"id":"01818c5e-efb9-59c4-b339-08b834294232","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"313e84c5-8bc7-5150-826a-467ea7252acd","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"2597db24-8ec5-54d4-86ad-8082be50f4f6","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"38f24092-0019-582d-86bf-d1f61bccde1d","slug":"changes","fullItemName":"Changes"},{"id":"cdc15e74-0503-53a5-a4be-c53ec4e20898","slug":"update","fullItemName":"Update"}]},{"id":"73d0cf59-f9c0-5785-8c74-e756826d5d1e","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"64b11689-d52a-560f-8d9b-c592d654615e","slug":"goals","fullItemName":"Goals"},{"id":"ac3d1637-467f-5edb-8fd8-73f66160080f","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"4bffe5b2-0ce0-5ae8-8c0b-914bb6ed5a1d","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"82441da5-60f5-53b4-b510-187f7bacb4a8","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"3e5817d5-30e7-54b7-b9ba-224b4a295bba","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"b30bb006-efbc-5a69-90f3-30abf232a97d","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"84dc0da0-8533-5c5d-99f6-7c04a116701a","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"45d8d35d-9757-544c-b04e-9747898a1f0e","slug":"definition","fullItemName":"Definition"},{"id":"21acb832-e5e8-5bd1-9b8d-9410ec5011bf","slug":"causes-risk-factors","fullItemName":"Causes and risk factors"},{"id":"cf27bd7b-b787-5def-bb40-ee0f134a8aca","slug":"prevalence","fullItemName":"Prevalence"},{"id":"a55a1739-f3d2-534c-b533-f6406d9c81ea","slug":"complications","fullItemName":"Complications"},{"id":"683b612a-3f1d-5580-951b-e14672f52b4a","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"dbc94220-a914-56d0-883d-d158da511e1c","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"57b3b7a5-9042-53fa-a236-56d0d02b647e","slug":"assessment","fullItemName":"Assessment"},{"id":"35ee8784-602e-5a29-9ccf-65b3c3f940d2","slug":"interpretation-of-abpi","fullItemName":"Interpretation of ABPI"},{"id":"0c766f2c-0c8f-521b-85fd-e947ba6b2d09","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"5e199f8a-7621-5318-9da1-264db8f544b8","fullItemName":"Management","slug":"management","subChapters":[{"id":"c8bda10b-ebb6-533b-9c91-96efa5ddf0c3","slug":"venous-leg-ulcers","fullItemName":"Scenario: Venous leg ulcers"}]},{"id":"e084faba-a409-53ac-aa53-08b80a3991f1","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"66a7f656-c6f5-57a2-a08a-1533a6fd4e92","slug":"clarithromycin","fullItemName":"Clarithromycin"},{"id":"a6cda703-9039-5115-b3d3-478cdb4d1e55","slug":"co-amoxiclav","fullItemName":"Co-amoxiclav"},{"id":"1cf75cbb-8bc4-58cc-9a1b-11516db5ad2c","slug":"co-trimoxazole","fullItemName":"Co-trimoxazole"},{"id":"3f0efc32-779b-56f6-85ca-e46a59745bed","slug":"doxycycline","fullItemName":"Doxycycline"},{"id":"fe306aab-d8d7-5181-a461-128f2aa3c65a","slug":"erythromycin","fullItemName":"Erythromycin"},{"id":"314a80d5-e16b-5625-8d64-4141535ff392","slug":"flucloxacillin","fullItemName":"Flucloxacillin"},{"id":"b7e7b8ec-799c-5ea5-9ac0-11935f899b8a","slug":"oral-analgesia","fullItemName":"Oral analgesia"},{"id":"43ed3b03-6322-5690-8f85-b6e10a0b3d3e","slug":"pentoxifylline","fullItemName":"Pentoxifylline"}]},{"id":"19f3ffbe-f365-5196-8586-0dceeaf69908","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"89207239-b8a4-50ce-8b2d-3065a830c0af","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"45831e7c-0e6f-50f3-a513-fe4fcacff65e","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"3d90cdb0-b2fd-5bfd-bd2d-342e36901f9d","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"8b66d1a4-6ee5-5556-b671-204219a81787","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"5b8ee442-8da6-524f-bf34-e6a9cc2a771e","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"6fa96be3-beae-51f6-9f1c-4d278b058d09","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"e75dc366-237b-55d2-a654-2e3bf503b955","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"e084faba-a409-53ac-aa53-08b80a3991f1","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"15b95b74-41b2-59b6-ad3a-bc0f4d7b13f2","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 35db8728-492b-4d0d-9bc7-a74500bec1ae --><h3>What are the contraindications and cautions for pentoxifylline?</h3><!-- end field 35db8728-492b-4d0d-9bc7-a74500bec1ae -->","summary":"","htmlStringContent":"<!-- begin item cb13351d-78cf-4b4e-894c-a74500bec2ab --><!-- begin field 8de9867b-1903-4d1a-9dd2-a74500bec1ae --><ul><li><strong>Do not prescribe pentoxifylline to:</strong><ul><li>People with:<ul><li>Recent cerebral haemorrhage.</li><li>Recent retinal haemorrhage.</li><li>Acute myocardial infarction.</li><li>Severe cardiac arrhythmias.</li><li>Acute porphyria. </li></ul></li><li>Pregnant women — the manufacturer does not recommend the use of pentoxifylline during pregnancy due to a lack of information on the use in human pregnancy. However, no untoward effects have been found in animal studies. </li></ul></li><li><strong>Prescribe pentoxifylline with caution to:</strong><ul><li>People with:<ul><li>Hypotension.</li><li>Coronary artery disease.</li><li>Diabetes (may lower blood glucose levels).</li><li>Severe hepatic impairment — manufacturer advises consideration of a dose reduction.</li><li>Renal impairment — reduce dose by 30–50% if estimated glomerular filtration rate (eGFR) is less than 30 mL/minute/1.73 m<sup>2</sup>.</li></ul></li><li>Breastfeeding women — the manufacturer advises use only if the potential benefit outweighs the risk. Pentoxifylline passes into breast milk in minute quantities. </li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/leg-ulcer-venous/references/\">ABPI, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/leg-ulcer-venous/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field 8de9867b-1903-4d1a-9dd2-a74500bec1ae --><!-- end item cb13351d-78cf-4b4e-894c-a74500bec2ab -->","subChapters":[]},{"id":"f4971b9d-dfa4-51ef-b86c-4b756e89dbde","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 83ce4530-6af7-4e22-ae15-a74500beaa14 --><h3>What are the adverse effects of pentoxifylline?</h3><!-- end field 83ce4530-6af7-4e22-ae15-a74500beaa14 -->","summary":"","htmlStringContent":"<!-- begin item c9f145a0-2a52-4986-88af-a74500beab20 --><!-- begin field 93609831-596c-443d-9f2e-a74500beaa14 --><ul><li><strong>The following adverse effects have been reported in clinical trials or post-marketing studies (frequencies are unknown):</strong><ul><li>Arrhythmia, tachycardia, and angina.</li><li>Thrombocytopenia, leukopenia/neutropenia.</li><li>Dizziness, headache, aseptic meningitis (predominantly in people with underlying connective tissue disorders). </li><li>Gastrointestinal disorder, epigastric discomfort, abdominal distension, nausea, vomiting, diarrhoea, constipation, and hypersalivation.</li><li>Pruritus, erythema, urticaria, hot flush, and rash.</li><li>Anaphylactic reactions, anaphylactoid reaction, and angioedema.</li><li>Cholestasis.</li><li>Agitation and sleep disorder.</li><li>Bronchospasm.</li><li>Hypotension and haemorrhage.<ul><li>A few very rare events of bleeding have been reported in people treated with pentoxifylline with and without anticoagulants or platelet aggregation inhibitors. The serious cases are predominantly concentrated in the gastrointestinal, genitourinary, multiple site, and surgical wound areas and are associated with bleeding risk factors. A causal relationship between pentoxifylline and bleeding has not been established. Thrombocytopenia has occurred in isolated cases.</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/leg-ulcer-venous/references/\">ABPI, 2016</a>]</p><!-- end field 93609831-596c-443d-9f2e-a74500beaa14 --><!-- end item c9f145a0-2a52-4986-88af-a74500beab20 -->","subChapters":[]},{"id":"8a1cf694-594e-54bf-aedc-ed4c0a106d4b","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 7556567c-e8dd-4246-91ad-a74500bed39e --><h3>What are the possible drug interactions with pentoxifylline?</h3><!-- end field 7556567c-e8dd-4246-91ad-a74500bed39e -->","summary":"","htmlStringContent":"<!-- begin item eaa0aef8-3784-4cfa-bb23-a74500bed3d5 --><!-- begin field c50acf3e-0300-4ae3-b90f-a74500bed39e --><ul><li><strong>Possible drug interactions with pentoxifylline include:</strong><ul><li><strong>Anticoagulants </strong>— post-marketing cases of increased anticoagulant activity have been reported in people concurrently treated with pentoxifylline and an anticoagulant.<ul><li>Monitoring of anticoagulant activity in these people is recommended when pentoxifylline is introduced or the dose is changed.</li></ul></li><li><strong>Antihypertensive drugs</strong> — pentoxifylline may potentiate the effect of antihypertensive drugs.<ul><li>The dose of the antihypertensive drug may need to be reduced. </li></ul></li><li><strong>Antiplatelets (such as aspirin, clopidogrel, dipyridamole)</strong> — concurrent use may result in an increased risk of bleeding.<ul><li>The manufacturer of pentoxifylline advises that concurrent use should be done with caution.</li></ul></li><li><strong>Cimetidine </strong>— concurrent use with pentoxifylline may increase the plasma concentrations of pentoxifylline and the active metabolite lisofylline.</li><li><strong>Nonsteroidal anti-inflammatory drugs (NSAIDs) </strong>— concurrent use may result in an increased risk of bleeding.<ul><li>The manufacturer of pentoxifylline advises that concurrent use should be done with caution.</li></ul></li><li><strong>Theophylline and </strong><strong>aminophylline</strong> — concurrent use with pentoxifylline may increase theophylline or aminophylline levels. <ul><li>For theophylline, manufacturer advises to monitor and adjust dose.</li><li>For aminophylline, manufacturer advises to use with caution or avoid.</li></ul></li><li><strong>Ciprofloxacin </strong>— ciprofloxacin very slightly increases the exposure to pentoxifylline. <ul><li>Manufacturer advises to monitor for adverse effects. </li></ul></li><li><strong>Fluvoxamine</strong> — fluvoxamine is predicted to increase the exposure to pentoxifylline.<ul><li>Manufacturer makes no recommendation.</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/leg-ulcer-venous/references/\">ABPI, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/leg-ulcer-venous/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field c50acf3e-0300-4ae3-b90f-a74500bed39e --><!-- end item eaa0aef8-3784-4cfa-bb23-a74500bed3d5 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}